Skip header and navigation

2 records – page 1 of 1.

A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.

https://arctichealth.org/en/permalink/ahliterature15782
Source
Allergy. 1997 Aug;52(8):853-9
Publication Type
Article
Date
Aug-1997
Author
O T Olsen
K R Larsen
L. Jacobsan
U G Svendsen
Author Affiliation
Department of Pulmonery Medicine and Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Source
Allergy. 1997 Aug;52(8):853-9
Date
Aug-1997
Language
English
Publication Type
Article
Keywords
Adolescent
Adrenergic beta-Agonists - therapeutic use
Adult
Antigens, Dermatophagoides
Asthma - diagnosis - drug therapy - therapy
Bronchial Provocation Tests
Double-Blind Method
Female
Forced expiratory volume
Glycoproteins - administration & dosage - adverse effects - immunology
Humans
Immunoglobulin E - analysis - blood - immunology
Immunotherapy
Male
Middle Aged
Peak Expiratory Flow Rate
Severity of Illness Index
Skin Tests
Steroids - therapeutic use
Vital Capacity
Abstract
Thirty-one adult patients with asthma caused by house-dust mites (HDM) were included in this placebo-controlled, double-blind study to evaluate the efficacy and safety of specific immunotherapy (SIT) with biologically standardized extracts of HDM. The specific diagnosis was confirmed by skin prick tests, specific IgE, and bronchial provocation tests with HDM allergens. The patients were randomized to receive active treatment with extracts of either Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark) or placebo injections. Twenty-three patients completed the study. After 1 year of treatment, we found a clinically important and significant reduction in both asthma medicine consumption (inhaled steroids 38% and beta 2-agonists 46%) and symptom score (57%) in the actively treated group, but not the placebo group. These findings were confirmed by a significant decrease in skin and bronchial sensitivity to HDM in the active group. Additionally, there was a significant difference in the patients' scores for effect in favor of the actively treated group. Total IgE and specific IgE to HDM showed no significant changes before and after treatment for either group. Spirometric lung-function measurements showed a significant increase in forced expiratory volume in 1 s (FEV1) from 85% before to 89% of predicted values after treatment for the actively treated group. Peak-flow measurements at home showed no significant changes during the study. It is concluded that allergen SIT is an effective treatment in adult patients suffering from asthma due to HDM.
PubMed ID
9284985 View in PubMed
Less detail

[Primary lung cancer in patients under 40 years of age]

https://arctichealth.org/en/permalink/ahliterature23657
Source
Ugeskr Laeger. 1994 May 16;156(20):3018-21
Publication Type
Article
Date
May-16-1994
Author
K R Larsen
G W Grode
O T Olsen
Author Affiliation
Medicinsk/lungemedicinsk afdeling Y, Amtssygehuset i Gentofte.
Source
Ugeskr Laeger. 1994 May 16;156(20):3018-21
Date
May-16-1994
Language
Danish
Publication Type
Article
Keywords
Adult
Age Factors
Denmark - epidemiology
English Abstract
Female
Humans
Lung Neoplasms - diagnosis - epidemiology - etiology
Male
Sex Factors
Abstract
There seems to be a resistance of patients and physicians towards aggressive diagnostic evaluation of the symptoms of lung cancer in young people. We here review nine series of young patients with primary lung cancer. Patients below 40 years of age represent between 1.2 and 5% of the total lung cancer population. The distribution of sex and histopathologic findings is different, there being more women, fewer cases of squamous cell and more cases of small anaplastic and adenocarcinoma in the young group. Between 87 and 96% are smokers. There is a delay from the debut of symptoms to the first contact with a general physician of 2.4 to 10.8 months. There is a wide variation concerning tendency to operate with a frequency of curative resection of between 15 and 57%. Based on the survival of young patients who are treated by curative surgical resection, the outcome of surgical treatment for young patients does not differ from the general experience concerning resection in patients of all ages. Young patients who are found inoperable have worse survival than the older patients. Seventy to 90%, more than in the group of patients of all ages, have stadium II or III at the time of diagnosis. In conclusion, physicians should be aggressive with respect to the diagnostic evaluation even of young patients with symptoms suggestive of lung cancer.
PubMed ID
8023407 View in PubMed
Less detail